New York, NY, United States of America

Peter Bohlen


 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2008-2012

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovations of Peter Bohlen

Introduction

Peter Bohlen is a notable inventor based in New York, NY, with a focus on advancements in biotechnology. He holds three patents that contribute significantly to the field of medical science, particularly in the development of monoclonal antibodies.

Latest Patents

His latest patents include innovative antibodies against vascular endothelial growth factor receptor-1 (VEGFR-1). These monoclonal antibodies are specifically designed to target VEGFR-1, providing nucleotide sequences that encode and amino acid sequences comprising variable heavy and light chain immunoglobulin molecules. This invention also details the complementarity determining regions of CDR1, CDR2, and CDR3. Furthermore, it outlines methods for generating and expressing anti-VEGFR-1 antibodies, as well as therapeutic approaches for treating angiogenic-related disorders and reducing tumor growth through the administration of these antibodies.

Career Highlights

Throughout his career, Peter Bohlen has made significant contributions while working with prominent companies such as Imclone LLC and Imclone Systems, Inc. His work has been pivotal in advancing the understanding and treatment of various medical conditions.

Collaborations

Peter has collaborated with notable colleagues, including Yan Wu and Daniel J Hicklin, enhancing the impact of his research and innovations.

Conclusion

Peter Bohlen's contributions to biotechnology through his patents and collaborations highlight his role as a significant inventor in the field. His work continues to influence the development of treatments for critical health issues.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…